Skip to main content
Premium Trial:

Request an Annual Quote

Caliper s Revenues Grow 22 Percent in Q3 As Pharmas Buy Into Its Microfluidic Screening Platform

NEW YORK, Nov. 5 (GenomeWeb News) - Caliper Life Sciences yesterday reported a 22-percent jump in third-quarter revenues and a shrinking loss as pharmaceutical companies adopt its microfluidic screening platform.

 

Revenues for the quarter ended Sept. 30 increased to $20.2 million from $16.5 million during the same period last year. Caliper said that during the last three months, Merck, Johnson & Johnson, and Taisho Pharmaceutical of Japanhad each purchased a LabChip 3,000 microfluidic screening system for the first time. In addition, Aventis and Pfizer recently bought additional systems, according to the company. 

 

Caliper spent $5.3 million on R&D during the quarter, down from $8.8 million a year ago.

 

The company's net loss was cut in half, to $5.1 million, or $.17 per share, compared to $10.1 million, or $.37 per share, during the third quarter of 2003.

 

As of Sept. 30, Caliper had $6.1 million in cash and cash equivalents and $43.1 million in short-term marketable securities.

The Scan

Pig Organ Transplants Considered

The Wall Street Journal reports that the US Food and Drug Administration may soon allow clinical trials that involve transplanting pig organs into humans.

'Poo-Bank' Proposal

Harvard Medical School researchers suggest people should bank stool samples when they are young to transplant when they later develop age-related diseases.

Spurred to Develop Again

New Scientist reports that researchers may have uncovered why about 60 percent of in vitro fertilization embryos stop developing.

Science Papers Examine Breast Milk Cell Populations, Cerebral Cortex Cellular Diversity, Micronesia Population History

In Science this week: unique cell populations found within breast milk, 100 transcriptionally distinct cell populations uncovered in the cerebral cortex, and more.